zikv

Theaflavin 3,3'-digallate, a major polyphenol found in black tea, is an inducer of oxidative stress which has anti-inflammatory and cancer chemopreventive actions, it reduces tumor angiogenesis by downregulating HIF-1αand VEGF.

ZIKV-IN-8 (Compound 9b) is a non-competitive inhibitor of the Zika virus (ZIKV). It demonstrates optimal anti-ZIKV activity with a selectivity index of 22.4. ZIKV-IN-8 significantly inhibits ZIKV, with an IC50 value of 25.6 μM, and is suitable for ZIKV infection research.

DENV-2/ZIKV-IN-1 (Compd 16a) is a dual inhibitor of dengue virus (DENV) and Zika virus (ZIKV), exhibiting EC50 values of 1.4 μM and 2.4 μM, respectively.

ZIKV-IN-1 is a potent inhibitor of Zika virus (EC50: 2.8 μM, EC90: 6.8 μM) with anti-ZIKV effects and low cytotoxicity, showing high affinity for the RdRp domain of ZIKV.

ZIKV-IN-4 is a low cytotoxic, acid-stable anti-ZIKV agent with an EC50 value of 3.49 μM. ZIKV-IN-4 exhibited potent inhibition of ZIKV NS5 MTase.

ZIKV-IN-2 is a potent inhibitor of ZIKV NS5 methyltransferase (MTase) (IC50: 38.86 μM) and inhibits the replication and infection of ZIKV, which can be used to study Zika virus (ZIKV).

ZIKV-IN-5 is an acid-stable, low cytotoxic anti-ZIKV agent with an EC50 value of 0.71 μM. ZIKV-IN-5 showed effective inhibition of ZIKV NS5 MTase activity.

ZIKV-IN-K22 is a potent antiviral agent against a broad range of coronaviruses by targeting membrane-bound viral RNA replication, effectively inhibiting ZIKV with IC50 of 2.1 μM.

ZIKV-IN-3, a derivative of andrographolide, serves as a potent inhibitor of the Zika virus (ZIKV) NS5 methyl transferase (MTase), showcasing an IC50 of 18.34 μM. It effectively curtails ZIKV replication and infection, making it valuable in Zika virus research.

ZIKV-IN-6 (compound 22) is a direct inhibitor of the Zika virus (ZIKV) that binds to its RNA-dependent RNA polymerase (RdRp), obstructing viral RNA synthesis mediated by the ZIKV NS5 protein. The compound exhibits low cytotoxicity (CC50 >50 μM) and mitigates excessive inflammatory response and pyroptosis [1].

T-1105 is a broad-spectrum antiviral inhibitor.

ML-SA1 (Mucolipin synthetic agonist 1) is a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively[1].

Azaribine (2;,3;,5;-Tri-O-acetyl-6-azauridine) is an orotate monophosphate decarboxylase (OMPD) inhibitor with broad-spectrum antiviral activity, inhibiting viral genome replication and gene transcription.Azaribine has been used in the study of Zika virus (ZIKV) infections, and in the study of psoriasis, arthritis and mycosis fungoides. Azaribine is used to study Zika virus (ZIKV) infections, psoriasis and mycosis fungoides.

LabMol-319 is a potent Zika virus (ZIKV) NS5 RdRp inhibitor with antiviral activity for the study of ZIKV virus.

SN 2 is a novel and potent TRPML3 ion channel activator(EC50 of 1.8±0.13 μM).

SMU-1k is a potent broad-spectrum antiviral agent. It exhibits inhibitory activity against ZIKV and DENV-2, with EC50 values of 7.08 μM and 3.96 μM, respectively. SMU-1k significantly suppresses the expression of NS5 protein and restores the levels of STAT2.

Antiviralagent 54 (compound 33) is a broad-spectrum, orally active antiviral agent. It demonstrates antiviral activity against ZIKV, HCoV-OC43, and influenza A virus (IVA). Antiviralagent 54 also reduces ZIKV RNA and protein levels.

GNF-2-deg is a PROTAC degrader that targets the envelope protein of the dengue virus (DENV E protein), achieving a DC50 of 0.83 μM. It inhibits viral entry by preventing membrane fusion mediated by the E protein and demonstrates antiviral activity against DENV 2 through protein degradation, with an EC90 of 3.5 μM. Additionally, GNF-2-deg shows antiviral efficacy against ZIKV, JEV, WNV, and YFV, with EC90 values ranging from 1.96 to 7.79 μM.

NSC-323241 is a potent inhibitor of STT3A-mediated mega protein complex assembly. It disrupts the large endoplasmic reticulum (ER) complexes localized by STT3A during dengue virus (DENV) and Zika virus (ZIKV) infections. NSC-323241 interferes with the binding of the STT3A subcomplex to viral non-structural proteins (such as NS2B, NS3) and host transporter proteins, thus impairing the formation of the viral replication microenvironment. This compound holds promise for researching flavivirus infections, including dengue and Zika viruses.

RYL-634 is a potent broad-spectrum antiviral agent. It exerts its antiviral effects by inhibiting the activity of human dihydroorotate dehydrogenase (HsDHODH), thereby blocking the pyrimidine supply necessary for viral replication. RYL-634 demonstrates significant inhibitory action against various viruses, with EC50 values of 7 nM for DENV, 20 nM for ZIKV, 4 nM for EV71, 5 nM for HCV, and 13 nM for HIV. This compound can be used for research into diseases associated with multiple viral infections.

MTase-IN-2 (compound 32) is a potent inhibitor of the NS5 methyltransferase enzyme, exhibiting IC50 values of 2.14 μM against the Dengue virus (Dengue virus) (DENV3) MTase domain and 2.01 μM against the Zika virus (ZIKV) NS5 MTase domain.

IRBM-Z-1 is a non-competitive inhibitor of Zika virus (ZIKV) NS2B-NS3 protease with an IC50 of 1.8 μM. It also inhibits the mutated Dengue virus type 2 (DENV2) and West Nile virus (WNV) NS2B-NS3 proteases, exhibiting IC50 values of 3.9 μM and 4.7 μM, respectively. IRBM-Z-1 effectively inhibits Zika virus replication and reduces virus-induced cytopathic effects, making it useful for research related to ZIKV infection.

IRBM-Z-2 is a non-competitive, orally active inhibitor of the Zika virus (ZIKV) NS2B-NS3 protease, with IC50 values of 0.04 μM for the wild-type and 3.1 μM for the I156T mutant strain. It shows broad-spectrum antiviral potential against flaviviruses, with IC50 values of 2.1 μM for Dengue virus 2 (DENV2) and 0.09 μM for West Nile virus (WNV) NS2B-NS3 proteases. Additionally, IRBM-Z-1 inhibits Zika virus replication and alleviates virus-induced cytopathic effects, making it useful for studies related to ZIKV infection.

p-nitro-Pifithrin-α is a cell-permeable analog of pifithrin-α, a potent p53 inhibitor. It suppresses p53-mediated TGF-β1 expression in HK-2 cells and inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. Moreover, p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice subjected to a high-fat diet, mitigating the effects of non-alcoholic fatty liver disease [1] [2] [3] [4].